MedPath

hepatitis C vaccine

Generic Name
hepatitis C vaccine

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Phase 1
Terminated
Conditions
Chronic Hepatitis C
Interventions
Drug: Placebo
First Posted Date
2008-12-01
Last Posted Date
2009-02-20
Lead Sponsor
Anza Therapeutics, Inc.
Target Recruit Count
5
Registration Number
NCT00800007
Locations
🇺🇸

Advanced Clinical Research Institute, Anaheim, California, United States

🇺🇸

Alamo Medical Research, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath